US Stock Insider Trading | Treace Medical disclosed 1 insider transaction on February 11

K-LinePoet · 2026-02-25T04:38:33+00:00

On February 11, 2026, Treace Medical executive Scanlan Sean F. purchased 16,900 shares at a price of $1.05 on February 10, having previously engaged in multiple stock buy and sell transactions. The company focuses on improving the treatment of bunions and related midfoot deformities.

K-LinePoet

2026-02-25 04:38:33

Abstract generation in progress

On February 11, 2026, Treace Medical (TMCI) disclosed one insider transaction. Executive Scanlan Sean F. purchased 16,900 shares on February 10, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 11, 2026	Executive	Scanlan Sean F.	February 10, 2026	Buy	16,900	1.05	17,700
July 22, 2025	Executive	Scanlan Sean F.	July 18, 2025	Buy	33,400	0.72	24,000
May 12, 2025	Executive	Elder Scot Michael	May 8, 2025	Sell	1,894	7.54	14,300
March 19, 2025	Executive	Scanlan Sean F.	March 17, 2025	Buy	50,000	1.05	52,500
March 19, 2025	Executive	Scanlan Sean F.	March 17, 2025	Sell	50,000	7.97	398,500
March 4, 2025	Shareholder with >10%	Treace John T.	March 4, 2025	Buy	60,000	8.73	524,100
November 13, 2024	Executive	Elder Scot Michael	November 11, 2024	Sell	3,787	8.29	31,400
September 17, 2024	Shareholder with >10%	Treace John T.	September 16, 2024	Buy	50,000	5.31	265,600
September 16, 2024	Executive	Scanlan Sean F.	September 12, 2024	Buy	33,800	0.10	3,280.50
August 19, 2024	Director	TREACE JAMES T	August 15, 2024	Buy	84,000	5.96	501,000

[Company Information]

Treace Medical Concepts, Inc. was founded in July 2013 in Delaware. The company is a medical technology firm dedicated to improving the standard of care for bunion and related midfoot deformities. It pioneered the proprietary Lapiplasty 3D bunion correction system—a technique combining instruments, implants, and surgical methods designed to correct all three planes of bunion deformity surgically. To provide a comprehensive solution for midfoot deformities, the company launched the Adductoplasty System in 2021, integrating implants and precision instruments into the first fully integrated system designed for repeatable adjustment, stabilization, and fusion of the midfoot.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.